These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 12869732)

  • 1. Medicine. Drug deals diabetes a one-two punch.
    Couzin J
    Science; 2003 Jul; 301(5631):290. PubMed ID: 12869732
    [No Abstract]   [Full Text] [Related]  

  • 2. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
    Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.
    Doliba NM; Qin W; Najafi H; Liu C; Buettger CW; Sotiris J; Collins HW; Li C; Stanley CA; Wilson DF; Grimsby J; Sarabu R; Naji A; Matschinsky FM
    Am J Physiol Endocrinol Metab; 2012 Jan; 302(1):E87-E102. PubMed ID: 21952036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
    Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
    Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in the study of glucokinase and small molecule glucokinase activators].
    Li YQ; Feng ZQ; Song HR; Guo YS; Guo ZR
    Yao Xue Xue Bao; 2006 May; 41(5):390-4. PubMed ID: 16848312
    [No Abstract]   [Full Text] [Related]  

  • 9. A novel glucokinase activator modulates pancreatic islet and hepatocyte function.
    Efanov AM; Barrett DG; Brenner MB; Briggs SL; Delaunois A; Durbin JD; Giese U; Guo H; Radloff M; Gil GS; Sewing S; Wang Y; Weichert A; Zaliani A; Gromada J
    Endocrinology; 2005 Sep; 146(9):3696-701. PubMed ID: 15919746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of mangiferin as a potential Glucokinase activator by structure-based virtual ligand screening.
    Min Q; Cai X; Sun W; Gao F; Li Z; Zhang Q; Wan LS; Li H; Chen J
    Sci Rep; 2017 Mar; 7():44681. PubMed ID: 28317897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in glucokinase activators for the treatment of type 2 diabetes.
    Pal M
    Drug Discov Today; 2009 Aug; 14(15-16):784-92. PubMed ID: 19520181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
    Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
    Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.
    Dhanesha N; Joharapurkar A; Shah G; Kshirsagar S; Patel V; Patel K; Bahekar R; Jain M
    Eur J Pharmacol; 2013 Aug; 714(1-3):188-92. PubMed ID: 23810686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S 50131 and S 51434, two novel small molecule glucokinase activators, lack chronic efficacy despite potent acute antihyperglycaemic activity in diabetic mice.
    De Ceuninck F; Kargar C; Charton Y; Goldstein S; Perron-Sierra F; Ilic C; Caliez A; Rolin JO; Sadlo M; Harley E; Vinson C; Ktorza A
    Br J Pharmacol; 2013 Jul; 169(5):999-1010. PubMed ID: 23488540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
    Deshpande AM; Bhuniya D; De S; Dave B; Vyavahare VP; Kurhade SH; Kandalkar SR; Naik KP; Kobal BS; Kaduskar RD; Basu S; Jain V; Patil P; Chaturvedi Joshi S; Bhat G; Raje AA; Reddy S; Gundu J; Madgula V; Tambe S; Shitole P; Umrani D; Chugh A; Palle VP; Mookhtiar KA
    Eur J Med Chem; 2017 Jun; 133():268-286. PubMed ID: 28390958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fundamental bases of search of medicines for therapy of a diabetes mellitus type 2].
    Spasov AA; Petrov VI; Chepliaeva NI; Lenskaia KV
    Vestn Ross Akad Med Nauk; 2013; (2):43-9. PubMed ID: 23819328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 1-[4- [2-(4-bromobenzenesulfonamino) ethyl] phenylsulfonyl]-3-(trans-4-methylcyclohexyl)urea (I4), a new synthetic sulfonylurea compound, on glucose metabolism in vivo and in vitro.
    Wu GZ; Hong G; Zhang WP; Zhang HB
    Arzneimittelforschung; 2009; 59(11):550-6. PubMed ID: 20066963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.
    Baker DJ; Wilkinson GP; Atkinson AM; Jones HB; Coghlan M; Charles AD; Leighton B
    Br J Pharmacol; 2014 Apr; 171(7):1642-54. PubMed ID: 24772484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the liver on post-prandial glycaemia--emphasis on hepatic glucose uptake.
    Kawamori R
    Int J Clin Pract Suppl; 2000 Sep; (112):19-22. PubMed ID: 11064947
    [No Abstract]   [Full Text] [Related]  

  • 20. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA; Guzman-Perez A; Litchfield J; Aiello R; Treadway JL; Pettersen J; Minich ML; Filipski KJ; Jones CS; Tu M; Aspnes G; Risley H; Bian J; Stevens BD; Bourassa P; D'Aquila T; Baker L; Barucci N; Robertson AS; Bourbonais F; Derksen DR; Macdougall M; Cabrera O; Chen J; Lapworth AL; Landro JA; Zavadoski WJ; Atkinson K; Haddish-Berhane N; Tan B; Yao L; Kosa RE; Varma MV; Feng B; Duignan DB; El-Kattan A; Murdande S; Liu S; Ammirati M; Knafels J; Dasilva-Jardine P; Sweet L; Liras S; Rolph TP
    J Med Chem; 2012 Feb; 55(3):1318-33. PubMed ID: 22196621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.